Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 79 entries
Sorted by: Best Match Show Resources per page
Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure.

Hepatology (Baltimore, Md.)

Koelfat KVK, Picot D, Chang X, Desille-Dugast M, van Eijk HM, van Kuijk SMJ, Lenicek M, Layec S, Carsin M, Dussaulx L, Seynhaeve E, Trivin F, Lacaze L, Thibault R, Schaap FG, Olde Damink SWM.
PMID: 34133768
Hepatology. 2021 Nov;74(5):2670-2683. doi: 10.1002/hep.32017. Epub 2021 Aug 26.

BACKGROUND AND AIMS: Automated chyme reinfusion (CR) in patients with intestinal failure (IF) and a temporary double enterostomy (TDE) restores intestinal function and protects against liver injury, but the mechanisms are incompletely understood. The aim was to investigate whether...

Cite
Koelfat KVK, Picot D, Chang X, et al. Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure. Hepatology. 2021;74(5):2670-2683doi: 10.1002/hep.32017.
Koelfat, K. V. K., Picot, D., Chang, X., Desille-Dugast, M., van Eijk, H. M., van Kuijk, S. M. J., Lenicek, M., Layec, S., Carsin, M., Dussaulx, L., Seynhaeve, E., Trivin, F., Lacaze, L., Thibault, R., Schaap, F. G., & Olde Damink, S. W. M. (2021). Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure. Hepatology (Baltimore, Md.), 74(5), 2670-2683. https://doi.org/10.1002/hep.32017
Koelfat, Kiran V K, et al. "Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure." Hepatology (Baltimore, Md.) vol. 74,5 (2021): 2670-2683. doi: https://doi.org/10.1002/hep.32017
Koelfat KVK, Picot D, Chang X, Desille-Dugast M, van Eijk HM, van Kuijk SMJ, Lenicek M, Layec S, Carsin M, Dussaulx L, Seynhaeve E, Trivin F, Lacaze L, Thibault R, Schaap FG, Olde Damink SWM. Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure. Hepatology. 2021 Nov;74(5):2670-2683. doi: 10.1002/hep.32017. Epub 2021 Aug 26. PMID: 34133768; PMCID: PMC8596508.
Copy Download .nbib Format: NLM
[For patients with heart failure with preserved ejection fraction, is empagliflozine effective and safe for preventing cardiovascular mortality and heart failure hospitalization?].

La Revue de medecine interne

Lanthier L, Dussault C, Plourde MÉ, Cauchon M.
PMID: 34728091
Rev Med Interne. 2021 Nov;42(11):814-815. doi: 10.1016/j.revmed.2021.10.001. Epub 2021 Oct 30.

No abstract available.

Cite
Lanthier L, Dussault C, Plourde MÉ, et al. Chez les sujets avec insuffisance cardiaque à fraction d’éjection préservée, est-ce que l’empagliflozine est efficace pour prévenir la mortalité cardiovasculaire et l’hospitalisation pour insuffisance cardiaque tout en étant sécuritaire ? [For patients with heart failure with preserved ejection fraction, is empagliflozine effective and safe for preventing cardiovascular mortality and heart failure hospitalization?]. Rev Med Interne. 2021;42(11):814-815doi: 10.1016/j.revmed.2021.10.001.
Lanthier, L., Dussault, C., Plourde, M. �. �., & Cauchon, M. (2021). Chez les sujets avec insuffisance cardiaque à fraction d’éjection préservée, est-ce que l’empagliflozine est efficace pour prévenir la mortalité cardiovasculaire et l’hospitalisation pour insuffisance cardiaque tout en étant sécuritaire ? [For patients with heart failure with preserved ejection fraction, is empagliflozine effective and safe for preventing cardiovascular mortality and heart failure hospitalization?]. La Revue de medecine interne, 42(11), 814-815. https://doi.org/10.1016/j.revmed.2021.10.001
Lanthier, L, et al. "Chez les sujets avec insuffisance cardiaque à fraction d’éjection préservée, est-ce que l’empagliflozine est efficace pour prévenir la mortalité cardiovasculaire et l’hospitalisation pour insuffisance cardiaque tout en étant sécuritaire ?" [For patients with heart failure with preserved ejection fraction, is empagliflozine effective and safe for preventing cardiovascular mortality and heart failure hospitalization?]. La Revue de medecine interne vol. 42,11 (2021): 814-815. doi: https://doi.org/10.1016/j.revmed.2021.10.001
Lanthier L, Dussault C, Plourde MÉ, Cauchon M. Chez les sujets avec insuffisance cardiaque à fraction d’éjection préservée, est-ce que l’empagliflozine est efficace pour prévenir la mortalité cardiovasculaire et l’hospitalisation pour insuffisance cardiaque tout en étant sécuritaire ? [For patients with heart failure with preserved ejection fraction, is empagliflozine effective and safe for preventing cardiovascular mortality and heart failure hospitalization?]. Rev Med Interne. 2021 Nov;42(11):814-815. doi: 10.1016/j.revmed.2021.10.001. Epub 2021 Oct 30. French. PMID: 34728091.
Copy Download .nbib Format: NLM
A call for action to establish a research agenda for building a future health workforce in Europe.

Health research policy and systems

Kuhlmann E, Batenburg R, Wismar M, Dussault G, Maier CB, Glinos IA, Azzopardi-Muscat N, Bond C, Burau V, Correia T, Groenewegen PP, Hansen J, Hunter DJ, Khan U, Kluge HH, Kroezen M, Leone C, Santric-Milicevic M, Sermeus W, Ungureanu M.
PMID: 29925432
Health Res Policy Syst. 2018 Jun 20;16(1):52. doi: 10.1186/s12961-018-0333-x.

The importance of a sustainable health workforce is increasingly recognised. However, the building of a future health workforce that is responsive to diverse population needs and demographic and economic change remains insufficiently understood. There is a compelling argument to...

Cite
Kuhlmann E, Batenburg R, Wismar M, et al. A call for action to establish a research agenda for building a future health workforce in Europe. Health Res Policy Syst. 2018;16(1):52doi: 10.1186/s12961-018-0333-x.
Kuhlmann, E., Batenburg, R., Wismar, M., Dussault, G., Maier, C. B., Glinos, I. A., Azzopardi-Muscat, N., Bond, C., Burau, V., Correia, T., Groenewegen, P. P., Hansen, J., Hunter, D. J., Khan, U., Kluge, H. H., Kroezen, M., Leone, C., Santric-Milicevic, M., Sermeus, W., & Ungureanu, M. (2018). A call for action to establish a research agenda for building a future health workforce in Europe. Health research policy and systems, 16(1), 52. https://doi.org/10.1186/s12961-018-0333-x
Kuhlmann, Ellen, et al. "A call for action to establish a research agenda for building a future health workforce in Europe." Health research policy and systems vol. 16,1 (2018): 52. doi: https://doi.org/10.1186/s12961-018-0333-x
Kuhlmann E, Batenburg R, Wismar M, Dussault G, Maier CB, Glinos IA, Azzopardi-Muscat N, Bond C, Burau V, Correia T, Groenewegen PP, Hansen J, Hunter DJ, Khan U, Kluge HH, Kroezen M, Leone C, Santric-Milicevic M, Sermeus W, Ungureanu M. A call for action to establish a research agenda for building a future health workforce in Europe. Health Res Policy Syst. 2018 Jun 20;16(1):52. doi: 10.1186/s12961-018-0333-x. PMID: 29925432; PMCID: PMC6011393.
Copy Download .nbib Format: NLM
Once online poker, always online poker? Poker modality trajectories over two years.

Addictive behaviors reports

Dufour M, Morvannou A, Laverdière É, Brunelle N, Kairouz S, Nolin MA, Nadeau L, Dussault F, Berbiche D.
PMID: 32467840
Addict Behav Rep. 2020 Jan 17;11:100251. doi: 10.1016/j.abrep.2020.100251. eCollection 2020 Jun.

Online poker is considered more at-risk than land-based poker in terms of intense gambling behaviors and gambling problems. The development of many online gambling sites has raised public health concerns about the potential increase in online poker players. Longitudinal...

Cite
Dufour M, Morvannou A, Laverdière É, et al. Once online poker, always online poker? Poker modality trajectories over two years. Addict Behav Rep. 2020;11:100251doi: 10.1016/j.abrep.2020.100251.
Dufour, M., Morvannou, A., Laverdière, �. �., Brunelle, N., Kairouz, S., Nolin, M. A., Nadeau, L., Dussault, F., & Berbiche, D. (2020). Once online poker, always online poker? Poker modality trajectories over two years. Addictive behaviors reports, 11100251. https://doi.org/10.1016/j.abrep.2020.100251
Dufour, Magali, et al. "Once online poker, always online poker? Poker modality trajectories over two years." Addictive behaviors reports vol. 11 (2020): 100251. doi: https://doi.org/10.1016/j.abrep.2020.100251
Dufour M, Morvannou A, Laverdière É, Brunelle N, Kairouz S, Nolin MA, Nadeau L, Dussault F, Berbiche D. Once online poker, always online poker? Poker modality trajectories over two years. Addict Behav Rep. 2020 Jan 17;11:100251. doi: 10.1016/j.abrep.2020.100251. eCollection 2020 Jun. PMID: 32467840; PMCID: PMC7244906.
Copy Download .nbib Format: NLM
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.

Targeted oncology

Lin CC, Doi T, Muro K, Hou MM, Esaki T, Hara H, Chung HC, Helwig C, Dussault I, Osada M, Kondo S.
PMID: 33840050
Target Oncol. 2021 Jul;16(4):447-459. doi: 10.1007/s11523-021-00810-9. Epub 2021 Apr 11.

BACKGROUND: Patients with esophageal squamous cell carcinoma (SCC) have limited treatment options. Blocking transforming growth factor-β (TGFβ), which can be overexpressed in these tumors, may enhance responses to programmed cell death protein 1/programmed death-ligand 1 [PD-(L)1] inhibitors. Bintrafusp alfa...

Cite
Lin CC, Doi T, Muro K, et al. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia. Target Oncol. 2021;16(4):447-459doi: 10.1007/s11523-021-00810-9.
Lin, C. C., Doi, T., Muro, K., Hou, M. M., Esaki, T., Hara, H., Chung, H. C., Helwig, C., Dussault, I., Osada, M., & Kondo, S. (2021). Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia. Targeted oncology, 16(4), 447-459. https://doi.org/10.1007/s11523-021-00810-9
Lin, Chia-Chi, et al. "Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia." Targeted oncology vol. 16,4 (2021): 447-459. doi: https://doi.org/10.1007/s11523-021-00810-9
Lin CC, Doi T, Muro K, Hou MM, Esaki T, Hara H, Chung HC, Helwig C, Dussault I, Osada M, Kondo S. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia. Target Oncol. 2021 Jul;16(4):447-459. doi: 10.1007/s11523-021-00810-9. Epub 2021 Apr 11. PMID: 33840050; PMCID: PMC8266718.
Copy Download .nbib Format: NLM
Global health and health workforce development: what to learn from COVID-19 on health workforce preparedness and resilience.

The International journal of health planning and management

Kuhlmann E, Dussault G, Correia T.
PMID: 34051109
Int J Health Plann Manage. 2021 May;36:5-8. doi: 10.1002/hpm.3160.

This Special Issue is dedicated to the healthcare workers across the globe. It draws together studies from different disciplines and regions to identify important lessons learned on weaknesses as well as on opportunities for health workforce innovation through a...

Cite
Kuhlmann E, Dussault G, Correia T. Global health and health workforce development: what to learn from COVID-19 on health workforce preparedness and resilience. Int J Health Plann Manage. 2021;36:5-8doi: 10.1002/hpm.3160.
Kuhlmann, E., Dussault, G., & Correia, T. (2021). Global health and health workforce development: what to learn from COVID-19 on health workforce preparedness and resilience. The International journal of health planning and management, 365-8. https://doi.org/10.1002/hpm.3160
Kuhlmann, Ellen, et al. "Global health and health workforce development: what to learn from COVID-19 on health workforce preparedness and resilience." The International journal of health planning and management vol. 36 (2021): 5-8. doi: https://doi.org/10.1002/hpm.3160
Kuhlmann E, Dussault G, Correia T. Global health and health workforce development: what to learn from COVID-19 on health workforce preparedness and resilience. Int J Health Plann Manage. 2021 May;36:5-8. doi: 10.1002/hpm.3160. PMID: 34051109; PMCID: PMC8206822.
Copy Download .nbib Format: NLM
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.

Neuro-oncology advances

Khasraw M, Weller M, Lorente D, Kolibaba K, Lee CK, Gedye C, I de La Fuente M, Vicente D, Reardon DA, Gan HK, Scott AM, Dussault I, Helwig C, Ojalvo LS, Gourmelon C, Groves M.
PMID: 34056607
Neurooncol Adv. 2021 Apr 09;3(1):vdab058. doi: 10.1093/noajnl/vdab058. eCollection 2021.

BACKGROUND: For patients with recurrent glioblastoma (rGBM), there are few options following treatment failure with radiotherapy plus temozolomide. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the TGF-βRII receptor (a TGF-β "trap") fused...

Cite
Khasraw M, Weller M, Lorente D, et al. Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neurooncol Adv. 2021;3(1):vdab058doi: 10.1093/noajnl/vdab058.
Khasraw, M., Weller, M., Lorente, D., Kolibaba, K., Lee, C. K., Gedye, C., I de La Fuente, M., Vicente, D., Reardon, D. A., Gan, H. K., Scott, A. M., Dussault, I., Helwig, C., Ojalvo, L. S., Gourmelon, C., & Groves, M. (2021). Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neuro-oncology advances, 3(1), vdab058. https://doi.org/10.1093/noajnl/vdab058
Khasraw, Mustafa, et al. "Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma." Neuro-oncology advances vol. 3,1 (2021): vdab058. doi: https://doi.org/10.1093/noajnl/vdab058
Khasraw M, Weller M, Lorente D, Kolibaba K, Lee CK, Gedye C, I de La Fuente M, Vicente D, Reardon DA, Gan HK, Scott AM, Dussault I, Helwig C, Ojalvo LS, Gourmelon C, Groves M. Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neurooncol Adv. 2021 Apr 09;3(1):vdab058. doi: 10.1093/noajnl/vdab058. eCollection 2021. PMID: 34056607; PMCID: PMC8156979.
Copy Download .nbib Format: NLM
Discovery of .

Journal of medicinal chemistry

Reutershan MH, Machacek MR, Altman MD, Bogen S, Cai M, Cammarano C, Chen D, Christopher M, Cryan J, Daublain P, Fradera X, Geda P, Goldenblatt P, Hill AD, Kemper RA, Kutilek V, Li C, Martinez M, McCoy M, Nair L, Pan W, Thompson CF, Scapin G, Shizuka M, Spatz ML, Steinhuebel D, Sun B, Voss ME, Wang X, Yang L, Yeh TC, Dussault I, Marshall CG, Trotter BW.
PMID: 34714078
J Med Chem. 2021 Nov 11;64(21):16213-16241. doi: 10.1021/acs.jmedchem.1c01524. Epub 2021 Oct 29.

Identification of low-dose, low-molecular-weight, drug-like inhibitors of protein-protein interactions (PPIs) is a challenging area of research. Despite the challenges, the therapeutic potential of PPI inhibition has driven significant efforts toward this goal. Adding to recent success in this area,...

Cite
Reutershan MH, Machacek MR, Altman MD, et al. Discovery of . J Med Chem. 2021;64(21):16213-16241doi: 10.1021/acs.jmedchem.1c01524.
Reutershan, M. H., Machacek, M. R., Altman, M. D., Bogen, S., Cai, M., Cammarano, C., Chen, D., Christopher, M., Cryan, J., Daublain, P., Fradera, X., Geda, P., Goldenblatt, P., Hill, A. D., Kemper, R. A., Kutilek, V., Li, C., Martinez, M., McCoy, M., Nair, L., Pan, W., Thompson, C. F., Scapin, G., Shizuka, M., Spatz, M. L., Steinhuebel, D., Sun, B., Voss, M. E., Wang, X., Yang, L., Yeh, T. C., Dussault, I., Marshall, C. G., & Trotter, B. W. (2021). Discovery of . Journal of medicinal chemistry, 64(21), 16213-16241. https://doi.org/10.1021/acs.jmedchem.1c01524
Reutershan, Michael H, et al. "Discovery of ." Journal of medicinal chemistry vol. 64,21 (2021): 16213-16241. doi: https://doi.org/10.1021/acs.jmedchem.1c01524
Reutershan MH, Machacek MR, Altman MD, Bogen S, Cai M, Cammarano C, Chen D, Christopher M, Cryan J, Daublain P, Fradera X, Geda P, Goldenblatt P, Hill AD, Kemper RA, Kutilek V, Li C, Martinez M, McCoy M, Nair L, Pan W, Thompson CF, Scapin G, Shizuka M, Spatz ML, Steinhuebel D, Sun B, Voss ME, Wang X, Yang L, Yeh TC, Dussault I, Marshall CG, Trotter BW. Discovery of . J Med Chem. 2021 Nov 11;64(21):16213-16241. doi: 10.1021/acs.jmedchem.1c01524. Epub 2021 Oct 29. PMID: 34714078.
Copy Download .nbib Format: NLM
Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.

Molecular oncology

Gulley JL, Schlom J, Barcellos-Hoff MH, Wang XJ, Seoane J, Audhuy F, Lan Y, Dussault I, Moustakas A.
PMID: 34854206
Mol Oncol. 2021 Dec 01; doi: 10.1002/1878-0261.13146. Epub 2021 Dec 01.

Transforming growth factor-β (TGF-β) and programmed death-ligand 1 (PD-L1) initiate signaling pathways with complementary, nonredundant immunosuppressive functions in the tumor microenvironment (TME). In the TME, dysregulated TGF-β signaling suppresses antitumor immunity and promotes cancer fibrosis, epithelial-to-mesenchymal transition, and angiogenesis....

Cite
Gulley JL, Schlom J, Barcellos-Hoff MH, et al. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment. Mol Oncol. 2021;doi: 10.1002/1878-0261.13146.
Gulley, J. L., Schlom, J., Barcellos-Hoff, M. H., Wang, X. J., Seoane, J., Audhuy, F., Lan, Y., Dussault, I., & Moustakas, A. (2021). Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment. Molecular oncology, . https://doi.org/10.1002/1878-0261.13146
Gulley, James L, et al. "Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment." Molecular oncology vol. (2021). doi: https://doi.org/10.1002/1878-0261.13146
Gulley JL, Schlom J, Barcellos-Hoff MH, Wang XJ, Seoane J, Audhuy F, Lan Y, Dussault I, Moustakas A. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment. Mol Oncol. 2021 Dec 01; doi: 10.1002/1878-0261.13146. Epub 2021 Dec 01. PMID: 34854206.
Copy Download .nbib Format: NLM
MicroRNA Expression Profiling of Bone Marrow-Derived Proangiogenic Cells (PACs) in a Mouse Model of Hindlimb Ischemia: Modulation by Classical Cardiovascular Risk Factors.

Frontiers in genetics

Desjarlais M, Dussault S, Rivera JC, Chemtob S, Rivard A.
PMID: 32973881
Front Genet. 2020 Aug 21;11:947. doi: 10.3389/fgene.2020.00947. eCollection 2020.

BACKGROUND: Classical cardiovascular risk factors (CRFs) are associated with impaired angiogenic activities of bone marrow-derived proangiogenic cells (PACs) related to peripheral artery diseases (PADs) and ischemia-induced neovascularization. MicroRNAs (miRs) are key regulators of gene expression, and they are involved...

Cite
Desjarlais M, Dussault S, Rivera JC, et al. MicroRNA Expression Profiling of Bone Marrow-Derived Proangiogenic Cells (PACs) in a Mouse Model of Hindlimb Ischemia: Modulation by Classical Cardiovascular Risk Factors. Front Genet. 2020;11:947doi: 10.3389/fgene.2020.00947.
Desjarlais, M., Dussault, S., Rivera, J. C., Chemtob, S., & Rivard, A. (2020). MicroRNA Expression Profiling of Bone Marrow-Derived Proangiogenic Cells (PACs) in a Mouse Model of Hindlimb Ischemia: Modulation by Classical Cardiovascular Risk Factors. Frontiers in genetics, 11947. https://doi.org/10.3389/fgene.2020.00947
Desjarlais, Michel, et al. "MicroRNA Expression Profiling of Bone Marrow-Derived Proangiogenic Cells (PACs) in a Mouse Model of Hindlimb Ischemia: Modulation by Classical Cardiovascular Risk Factors." Frontiers in genetics vol. 11 (2020): 947. doi: https://doi.org/10.3389/fgene.2020.00947
Desjarlais M, Dussault S, Rivera JC, Chemtob S, Rivard A. MicroRNA Expression Profiling of Bone Marrow-Derived Proangiogenic Cells (PACs) in a Mouse Model of Hindlimb Ischemia: Modulation by Classical Cardiovascular Risk Factors. Front Genet. 2020 Aug 21;11:947. doi: 10.3389/fgene.2020.00947. eCollection 2020. PMID: 32973881; PMCID: PMC7472865.
Copy Download .nbib Format: NLM
Evaluation of the Tempo® System: Improving the Microbiological Quality Monitoring of Human Milk.

Frontiers in pediatrics

Cayer MP, Dussault N, de Grandmont MJ, Cloutier M, Lewin A, Brouard D.
PMID: 32984208
Front Pediatr. 2020 Sep 02;8:494. doi: 10.3389/fped.2020.00494. eCollection 2020.

No abstract available.

Cite
Cayer MP, Dussault N, de Grandmont MJ, et al. Evaluation of the Tempo® System: Improving the Microbiological Quality Monitoring of Human Milk. Front Pediatr. 2020;8:494doi: 10.3389/fped.2020.00494.
Cayer, M. P., Dussault, N., de Grandmont, M. J., Cloutier, M., Lewin, A., & Brouard, D. (2020). Evaluation of the Tempo® System: Improving the Microbiological Quality Monitoring of Human Milk. Frontiers in pediatrics, 8494. https://doi.org/10.3389/fped.2020.00494
Cayer, Marie-Pierre, et al. "Evaluation of the Tempo® System: Improving the Microbiological Quality Monitoring of Human Milk." Frontiers in pediatrics vol. 8 (2020): 494. doi: https://doi.org/10.3389/fped.2020.00494
Cayer MP, Dussault N, de Grandmont MJ, Cloutier M, Lewin A, Brouard D. Evaluation of the Tempo® System: Improving the Microbiological Quality Monitoring of Human Milk. Front Pediatr. 2020 Sep 02;8:494. doi: 10.3389/fped.2020.00494. eCollection 2020. PMID: 32984208; PMCID: PMC7492530.
Copy Download .nbib Format: NLM
Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure.

Hepatology (Baltimore, Md.)

Koelfat KVK, Picot D, Chang X, Desille-Dugast M, van Eijk HM, van Kuijk SMJ, Lenicek M, Layec S, Carsin M, Dussaulx L, Seynhaeve E, Trivin F, Lacaze L, Thibault R, Schaap FG, Olde Damink SWM.
PMID: 34133768
Hepatology. 2021 Nov;74(5):2670-2683. doi: 10.1002/hep.32017. Epub 2021 Aug 26.

BACKGROUND AND AIMS: Automated chyme reinfusion (CR) in patients with intestinal failure (IF) and a temporary double enterostomy (TDE) restores intestinal function and protects against liver injury, but the mechanisms are incompletely understood. The aim was to investigate whether...

Cite
Koelfat KVK, Picot D, Chang X, et al. Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure. Hepatology. 2021;74(5):2670-2683doi: 10.1002/hep.32017.
Koelfat, K. V. K., Picot, D., Chang, X., Desille-Dugast, M., van Eijk, H. M., van Kuijk, S. M. J., Lenicek, M., Layec, S., Carsin, M., Dussaulx, L., Seynhaeve, E., Trivin, F., Lacaze, L., Thibault, R., Schaap, F. G., & Olde Damink, S. W. M. (2021). Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure. Hepatology (Baltimore, Md.), 74(5), 2670-2683. https://doi.org/10.1002/hep.32017
Koelfat, Kiran V K, et al. "Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure." Hepatology (Baltimore, Md.) vol. 74,5 (2021): 2670-2683. doi: https://doi.org/10.1002/hep.32017
Koelfat KVK, Picot D, Chang X, Desille-Dugast M, van Eijk HM, van Kuijk SMJ, Lenicek M, Layec S, Carsin M, Dussaulx L, Seynhaeve E, Trivin F, Lacaze L, Thibault R, Schaap FG, Olde Damink SWM. Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure. Hepatology. 2021 Nov;74(5):2670-2683. doi: 10.1002/hep.32017. Epub 2021 Aug 26. PMID: 34133768; PMCID: PMC8596508.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 79 entries